- Home
- PENG vs MYGN Comparison
PENG vs MYGN Comparison
Compare PENG & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PENG
- MYGN
- Stock Information
- Founded
- PENG 1988
- MYGN 1991
- Country
- PENG Cayman Islands
- MYGN United States
- Employees
- PENG N/A
- MYGN N/A
- Industry
- PENG Semiconductors
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PENG Technology
- MYGN Health Care
- Exchange
- PENG Nasdaq
- MYGN Nasdaq
- Market Cap
- PENG 908.8M
- MYGN 744.7M
- IPO Year
- PENG 2017
- MYGN 1995
- Fundamental
- Price
- PENG $15.88
- MYGN $7.64
- Analyst Decision
- PENG Strong Buy
- MYGN Hold
- Analyst Count
- PENG 8
- MYGN 16
- Target Price
- PENG $24.94
- MYGN $20.17
- AVG Volume (30 Days)
- PENG 1.1M
- MYGN 1.0M
- Earning Date
- PENG 04-02-2025
- MYGN 05-06-2025
- Dividend Yield
- PENG N/A
- MYGN N/A
- EPS Growth
- PENG N/A
- MYGN N/A
- EPS
- PENG N/A
- MYGN N/A
- Revenue
- PENG $1,318,349,000.00
- MYGN $837,600,000.00
- Revenue This Year
- PENG $19.41
- MYGN $2.99
- Revenue Next Year
- PENG $8.94
- MYGN $8.36
- P/E Ratio
- PENG N/A
- MYGN N/A
- Revenue Growth
- PENG 8.05
- MYGN 11.21
- 52 Week Low
- PENG $14.20
- MYGN $7.35
- 52 Week High
- PENG $29.81
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- PENG N/A
- MYGN 28.54
- Support Level
- PENG N/A
- MYGN $7.69
- Resistance Level
- PENG N/A
- MYGN $8.27
- Average True Range (ATR)
- PENG 0.00
- MYGN 0.56
- MACD
- PENG 0.00
- MYGN 0.04
- Stochastic Oscillator
- PENG 0.00
- MYGN 17.37
About PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.